Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of 6 versus 12 weeks of sofosbuvir + velpatasvir for recent hepatitis C infection
2015-004243-39Phase 3Completed
- Sponsor
- University of New South Wales
- Start
- Nov 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sofosbuvir and velpatasvir in hepatitis C virus infection (2 arms), sponsored by University of New South Wales. Primary endpoint: SVR12. Started Nov 2016; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-004243-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004243-39.